- Exchange: Oslo
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Snapshot for Algeta ASA (ALGETA)
| Open: | 143.80 | Day's Range: | 141.30 - 144.00 | Volume: | 83,664 | Bid: | 142.50 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 141.50 | 52wk Range: | 121.52 - 218.64 | 1-Yr Rtn: | +1.53% | Ask: | 142.60 |
Stock Chart for ALGETA
Key Statistics for ALGETA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | 21.8611 |
| Earnings Per Share (NOK) (ttm) | -0.2448 |
| Est. EPS (NOK) (12/2012) | 6.5230 |
| Est. PEG Ratio | - |
| Market Cap (M NOK) | 6,063.21 |
| Shares Outstanding (M) | 42.52 |
| Enterprise Value (M NOK) (ttm) | 5,536.00 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 11.7797 |
| Price/Sale (ttm) | 21.6233 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/16/2012 |
More ALGETA Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for ALGETA
- Operating
- Investing
- Financing (M/NOK)
Company Profile & Key Executives for ALGETA
Algeta ASA operates in the pharmaceutical industry. The Company develops targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Algeta's compound Alpharadin is designed to treat bone metastases.
| Stein Holst AnnexstadChairman | John Edward BerrimanDeputy Chairman |
| Andrew Martin KayPresident/CEO | Oystein SougChief Financial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page